Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. PHARMACEUTICALS IN CHINA: FIRMS MONITORING

Executive Summary

U.S. PHARMACEUTICALS IN CHINA: FIRMS MONITORING the political climate in the Peoples Republic and hoping for winds favorable to trade in the wake of recent large scale unrest and continuing crackdowns against the popular democracy movement. In an informal survey of seven drug and biotech companies with business ventures in China, the consensus was that operations are continuing although not quite in a business-as-usual mode. Demand continues to slow at Warner-Lambert's new hard gelatin capsule manufacturing facility in Suzhou due to uncertainty in the marketplace among the Chinese companies supplied by the plant, a spokesperson indicated. The company's three non-Chinese employees have left the country. Suzhou is located about 45 miles northwest of Shanghai. "Business continues uninterrupted" at SmithKline's pharmaceutical manufacturing facility in Tianjin, about two hours from Beijing, according to a company official. However, SmithKline has "put on hold" plans for visitors to tour the plant. The facility, which employs approximately 200 Chinese nationals, produces several drugs, including Tagamet and Contac. SmithKline's Allergan contact lens business has two joint facilities through its International Hydron lens manufacturing unit. The recent situation in China has had "minimal effect on overall operations," which each have about 50 employees, 10 of whom are non-American foreigners, an Allergan spokesperson said. Johnson & Johnson has pulled its 17 non-Chinese employees out of the country, but business at its two joint venture plants "is pretty much status quo," the company said. J&J's Janssen Pharmaceutica operates one of the two plants, which will be fully operative later this year and will manufacture a wide range of prescription drugs, including antifungals, anthelmintics and anesthetics. An Upjohn spokesperson remarked that the business of supplying medical products "is not so politicized" as consumer goods joint venture arrangements. Upjohn has agreements with Chinese companies for the supply of medicinal herbs, but does not have any plants or people in the country. Searle, which has a March 1988 trust agreement to fund Chinese pharmaceutical development, also is waiting to see what happens. The biotech firm Cell Technology has "deferred indefinitely" plans to have one of the firm's head scientists go to China in August and is waiting to see whether the political situation will be "conducive to a meaningful relationship," a company spokesperson commented. The Boulder, Colorado-based biotech company signed an agreement in principle in April with the Chinese Medical Academy of Science for the joint development of biotechnology products.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel